Curetech gets FDA nod for liver cancer trial

The Clal Biotech portfolio company is testing its leading drug, CT-011.

Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio drug development company Curetech Ltd. has obtained US Food and Drug Administration (FDA) approval for a Phase I/II clinical trial for the treatment of liver cancer. Curetech's leading drug candidate, CT-011, is intended to treat hepatocellular carcinoma.

The trial aims to evaluate the safety and efficiency of CT-011 antibody in an open label format clinical trial. Curetech believes that the trial will include ten patients and will begin by the end of the year. The trial will be jointly conducted with Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA).

Curetech is meanwhile continuing the Phase II trial of CT-011 for the treatment of blood and colon cancers and the Phase I/II trial for the treatment of chronic hepatitis C.

Nochi Dankner-controlled IDB Holding Corp. Ltd. (TASE:IDBH) biotech holding company Clal Biotech owns 42% of Curetech.

Published by Globes [online], Israel business news - - on August 25, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018